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Abstract
Background: While the debate regarding shared clinical trial data has shifted from whether such data should be
shared to how this is best achieved, the sharing of data collected as part of systematic reviews has received little
attention. In this commentary, we discuss the potential benefits of coordinated efforts to share data collected as
part of systematic reviews.
Main body: There are a number of potential benefits of systematic review data sharing. Shared information and
data obtained as part of the systematic review process may reduce unnecessary duplication, reduce demand on
trialist to service repeated requests from reviewers for data, and improve the quality and efficiency of future
reviews. Sharing also facilitates research to improve clinical trial and systematic review methods and supports
additional analyses to address secondary research questions. While concerns regarding appropriate use of data,
costs, or the academic return for original review authors may impede more open access to information extracted as
part of systematic reviews, many of these issues are being addressed, and infrastructure to enable greater access to
such information is being developed.
Conclusion: Embracing systems to enable more open access to systematic review data has considerable potential
to maximise the benefits of research investment in undertaking systematic reviews.
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Background
The potential benefits of sharing clinical trial data have
been well documented. A move toward a more open sci-
ence of shared clinical data will enable replication of
analyses, reduce waste, promote secondary analyses, and
facilitate more efficient and robust evidence synthesis
[1–3]. In 2011, the Cochrane collaboration first called
for open access to data from all clinical trials [4], a view
which has been broadly supported by researchers [5],
international journals [6], and funding agencies [7].
While the debate regarding data sharing has shifted from
whether clinical trial data should be shared to how this
is best achieved, the sharing of data collected as part of
systematic reviews has received little attention.
The potential benefits of shared systematic
review data
A variety of information obtained from published manu-
scripts, reports or other repositories, or following
requests made directly to trial authors during the review
process could be made more accessible. Information
could include sample, effect size, and variability esti-
mates from individual trials used in pooled analyses,
information on trial methods or processes, or reviewer
classification or assessment (i.e. risk of bias) of trials.
Greater sharing of such information may offer a number
of potential benefits. First, as is the completion of a
clinical trial, undertaking quality systematic reviews is a
considerable task and is estimated to take well-
supported teams 12 months to complete [5]. Cochrane
reviews, for example, require multidisciplinary expertise
and resources to screen citations and extract data, to
contact trial authors for additional information, to assess
trial quality, and to analyse, interpret, and report review
findings. Shared information and data obtained as part
of the systematic review process may reduce unnecessary
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duplication, reduce demand on trialist to service
repeated requests from reviewers for data, and improve
the quality and efficiency of future reviews.
Second, data sharing may facilitate research to
improve clinical trial and systematic review methods.
Re-analysis of data from trials included in 146 meta-
analyses including 1346 trials provided empirical
evidence that inadequate allocation concealment or lack
of blinding significantly increased estimates of treatment
effects for subjective outcomes [8]. This finding was not
significant when examining trials with objective out-
comes. Further, analysis of data shared from trials by
authors of the Cochrane Review of interventions to pre-
vent obesity in childhood has been used to explore the
use of a tool to classify research trials as pragmatic and
explanatory [9]. The study identified that such study
design characteristics may be important effect modifiers
and recommended the tool be considered for use in
systematic reviews.
Third, shared data and information extracted from sys-
tematic reviews can also been used to support additional
analyses to address secondary research questions.
Secondary analyses of existing review data may be
particularly appealing for health policy makers and prac-
titioners interested in quickly identifying effective inter-
ventions relevant to their context. For example,
secondary analysis on trial data from a subset of studies
included in a recently updated Cochrane review [10] was
performed on behalf of health services to describe the
potential effectiveness of interventions delivered by usual
health service staff in reducing child exposure to tobacco
smoke [11]. The findings were used to inform local
health service practice regarding the type of support
provided. Each of these examples of the benefits of
shared systematic review data relied on agreement from
review authors to release extracted trial data for
re-analysis.
Barriers to data sharing
Clinical trialists report a number of barriers to sharing
clinical trial data, including concerns regarding appro-
priate use of data, costs associated with data sharing, or
the ability of the trialist to have a fair opportunity to first
publish research from the data set [1, 12, 13]. Such bar-
riers are likely to similarly impede the sharing of data
harvested through the process of a systematic review.
Any errors incurred in the original trial data extraction
process in systematic reviews would be perpetuated in
secondary analyses of such shared data. The lack of
standardisation on data extraction processes may result
in increased time required by the review team to prepare
information and data in a way that can be easily inter-
preted by those uninvolved in the extraction process.
Furthermore, review teams may perceive requests for
information and data extracted from reviews as
unwanted competition that may challenge their oppor-
tunity to publish research manuscripts utilising such
information, particularly when such use of data is not
appropriately acknowledged.
Moving forward: sharing of data extracted from
trials during reviews
Currently, much of the information from individual tri-
als obtained, extracted, and used in systematic reviews is
not provided in published reports. A more open and
coordinated approach to sharing review information
may help capitalise on the potential benefits of sharing
in a way that is considerate of the barriers and concerns
of review stakeholders. Specifically, the development of
infrastructure to centrally house and standardise data
extracted on trials by reviewers and with data quality
processes and criteria for data release may reduce the
time reviewers are required to attend to data requests
and may address concerns regarding appropriate use of
data [2]. To this end, the Agency for Healthcare Quality
and Research is funding a Systematic Review Data
Repository (SRDR) being developed by the Evidence-
based Practice Centre at Tufts Medical Centre [14]. The
SRDR will act as a central archive and data extraction
tool is freely accessible and enables researchers to
incorporate previously deposited data into their reviews.
Governance models and processes for enabling access
and use of data have been included in the SRDR initia-
tive to address some of the concerns regarding data
sharing. Similarly, the Open Science Framework, devel-
oped by the not for profit Centre for Open Science as a
means of improving collaboration in scientific research
allows workflow and archiving of all research materials,
including protocols and data sets, and provides user
controls on release of information.
While sharing data can increase academic citation
[15], systems to ensure appropriate acknowledgment of
original review authors responsible for deposited infor-
mation in any secondary analysis and methods to track
the use and impact of such information may increase
the academic incentive for sharing [1]. For clinical trials,
the International Committee of Medical Journal Editors
propose that, in order to be considered for publication
in its member journals (including leading medical jour-
nals such as BMJ, The Journal of American Medical
Association, and the Lancet), authors conducting
secondary analysis using shared data must cite the ori-
ginal data source including the unique trial identifier to
enable tracking of data use and invite collaboration by
the study team depositing data [16]. Such provisions
could similarly be extended to data collected via system-
atic reviews.
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Conclusions
The move toward more open system of data sharing is
gaining momentum. A recent survey of reviewers
affiliated with the Cochrane Collaborations Individual
Participant Data Review Group, for example, found that
83 % supported sharing of the data collected as part of
systematic reviews in a central repository [17]. While a
number of barriers to data sharing exist, for clinical
trials, these are being addressed, including in a recent
report by the Institute of Medicine (IOM), journal edi-
tors, and funding agencies [2, 3]. The experiences of the
SRDR and the recommendations of the IOM committee
and others would serve a sensible point of reference for
institutions publishing and supporting the production of
systematic reviews who are interested in increasing the
availability of data extracted as part of systematic
reviews.
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